AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06205797
Drug: Xeomin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xeomin® is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). It should be reconstituted with sterile, preservative-free 0.9% saline before use.~Other Names:~IncobotulinumtoxinA
Trial: NCT06112678
Drug: CKD-828, D097, D337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05702190
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of placebo as 2x5 drops on day 1, 3x10 drops on days 2-8, and 1x10 drops on day 9 in each study period.
Trial: NCT04854096
Drug: Best Available Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator
Trial: NCT06362265
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT05776927
Drug: Rescue Medication
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol 100μg / Albuterol 90μg
Trial: NCT04375800
Drug: 2 NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive 2 NRTIs per local label by mouth for 96 weeks as background therapy.
Trial: NCT05501470
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05456854
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo \*16 hr
Trial: NCT05431426
Drug: CH6001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6001 will be administered using the NEXThaler® DPI device
Trial: NCT04999020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dosing will consist of a loading dose followed by maintenance doses administered q8w. The maintenance dosing will be initiated 2 weeks after the loading dose is administered.
Trial: NCT05363839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered orally via a capsule.
Trial: NCT04748705
Drug: Placebo BID Tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take 1 tablet twice daily, each morning and evening, of randomly assigned study drug orally starting on Day 1 through study duration.
Trial: NCT05387785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered placebo capsule
Trial: NCT05294341
Drug: Norethindrone 0.35 MG
RxNorm normalized name: norethindrone 0.35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As specified in arm design
Trial: NCT04702997
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule containing an inert placebo
Trial: NCT06062953
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-9 mg flexible dosing before bed time
Trial: NCT06062953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-3 capsules flexible dosing before bed time
Trial: NCT06181513
Drug: Probiotic Blend Capsule
RxNorm normalized name: Probiotic Blend Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 million CFU (Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus helveticus, Bifidobacterium breve)
Trial: NCT05957822
Drug: TXA
RxNorm normalized name: TXA>2<
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tranexamic acid injection 8-10mg/kg
Trial: NCT05476770
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Give intrathecally:~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients ≥9 years of age
Trial: NCT05476770
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intrathecally.~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age ≥3 years of age - 24 mg~AML Patients:~Age 1-1.99 - 8 mg Age 2-2.99 - 10 mg Age 3-8.99 - 12 mg Age ≥9 years of age - 15 mg
Trial: NCT05525780
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A matched volume of placebo product will be administered to each subject in each cohort.
Trial: NCT05525780
Drug: Oral cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of Aricept tablet
Trial: NCT05978089
Drug: Yangxinshi tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment group was given Yangxinshi tablets (3 tablets/time and 3 times/day). The treatment period was 24 weeks.
Trial: NCT05978089
Drug: Yangxinshi tablet simulants
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group was given Yangxinshi tablet simulants (3 tablets/time and 3 times/day).The treatment period was 24 weeks.
Trial: NCT05718492
Drug: FOLFOX (oxaliplatin , leucovorin , fluorouracil , and fluorouracil )
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hepatic artery infusion chemotherapy. The FOLFOX (oxaliplatin 130 mg/m2, leucovorin 200 mg/m2, fluorouracil 400 mg/m2, and fluorouracil 2,400 mg/m2) regimen was sequentially infused through the catheter every cycle (3 weeks).
Trial: NCT06421376
Drug: Cardonilizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of Inductive therapy： nab-paclitaxel 250mg/ m2+cisplatin 75mg/ m2+Cardonilizumab 10mg/kg，ivgtt，3 weeks per cycle for 2 cycles
Trial: NCT05209256
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the alflutinib group received alflutinib (80 mg daily) until disease progression, unacceptable toxicity, or death.
Trial: NCT06092684
Drug: Ketanest®S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
Trial: NCT05751720
Drug: GIP/GLP-1a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group will receive GLP-1 analogues (subcutaneous Tirzepatide). The dose of Tirzepatide is 0.25 mg once weekly for 4 weeks then 0.5 mg once weekly.
Trial: NCT06156566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules, twice daily, 14 days.
Trial: NCT06719557
Drug: MK-1084
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT06719557
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral capsule (extended)
Trial: NCT06720324
Drug: Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fludarabine 30 mg/kg on day -5, -4, and -3; cyclophosphamide 300 mg/kg on day -5, -4, and -3; CD7-specific CAR-T Cells on day 0.
Trial: NCT05642026
Drug: Non steroidal anti-inflammatory drug and opioids
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group receive nonsteroidal and opioid pain medications (intravenous/oral inpatient and oral outpatient) per standard of care.
Trial: NCT06066710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given on the same schedule as the propranolol regime.
Trial: NCT05299099
Drug: IN-C006 inj.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN-C006 will be injected continuously for 3 days.
Trial: NCT05299099
Drug: RCN301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RCN301 will be injected continuously for 3 days.
Trial: NCT05872958
Drug: AZD3152
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD3152 will be administered via IM injection or IV infusion, as per the assigned arms.
Trial: NCT05335811
Drug: 4-[18F]Fluoro-1-Naphthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: By vein (IV)
Trial: NCT05667740
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT05884671
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive placebo during one of the sessions.
Trial: NCT04967092
Drug: Modified Xiao-Feng Powder + Antiallergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified Xiao-Feng Powder granules twice daily for 12 weeks plus Bilastine 20mg once daily for the first 6 weeks, and on-demand for the following 6 weeks.
Trial: NCT04933617
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 750 mg/m\^2 intravenous (IV) on Day 5 of each cycle up to 6 cycles
Trial: NCT04933617
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin 10 mg/m\^2/day continuous intravenous infusion (CIVI) on Days 1-4 of each cycle up to 6 cycles
Trial: NCT06542614
Drug: TQH3906 capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To assess the efficacy and safety of TQH3906 in subjects with moderate to severe plaque psoriasis.
Trial: NCT06542614
Drug: Placebo of TQH3906 capsules
RxNorm normalized name: PLACEBO CAP/TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without drug substance.
Trial: NCT05014815
Drug: histology-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05123599
Drug: ETV monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ETV monohydrate film-coated tablets will be administered orally.
Trial: NCT05123599
Drug: TAF
RxNorm normalized name: Altafed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAF film-coated tablets will be administered orally.
Trial: NCT04563026
Drug: DUR-928 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04563026
Drug: Placebo+ Standard of Care (SOC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT04310865
Drug: Yinhu Qingwen Granula
RxNorm normalized name: Saxifraga granulata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yinhu Qingwen Granula is a kind of herbal granula made from Yinhu Qingwen Decoction, which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
Trial: NCT04310865
Drug: Yin Hu Qing Wen Granula(low does)
RxNorm normalized name: Saxifraga granulata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
Trial: NCT01049633
Drug: Antibacterial, Antifungal, and Antiviral Prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad spectrum antimicrobial prophylaxis administered preoperatively
Trial: NCT01049633
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
Trial: NCT04683029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously or subcutaneously.
Trial: NCT06005441
Drug: CBL-A2 Injection
RxNorm normalized name: PROCYANIDIN A2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Provided as a ready for use injectable CBL-A2 solution
Trial: NCT06719908
Drug: AFA-281 is a small molecule, orally available
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a study to evaluate the interaction of AFA-281 with alcohol
Trial: NCT05045664
Drug: Experimental
RxNorm normalized name: WA-001 Experimental Soil Surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obinutuzumab with 2 x2 Gy involved site radiotherapy
Trial: NCT05813145
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 patients will receive four cycle of AC followed by paclitaxel 80 mg/m2 weekly for 12 week
Trial: NCT05178069
Drug: : Placebo for Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule manufactured without active ingredients.
Trial: NCT05185089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match orvepitant 30mg and 10mg tablets
Trial: NCT05480553
Drug: NPC-06
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Initial dose (Day 1) \<Dose\> An 18 mg/kg of NPC-06 will be injected by intravenous drip infusion once daily. The maximum dose of the test drug should not exceed 1,200 mg as fosphenytoin sodium.~   \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A 7.5 mg/kg of NPC-06 will be injected as needed by intravenous drip infusion once daily. The maximum dose of NPC-06 should not exceed 500 mg as fosphenytoin sodium.~\<Administration method\> Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds.
Trial: NCT05480553
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Initial dose (Day 1) \<Dose\> A placebo will be injected by intravenous drip infusion once daily. \<Administration method\> Dilute the study drug 3 to 4-fold using physiological saline for intravenous infusion and then administer the solution over 18 minutes.~2. Maintenance dose(Day 2～7) Maintenance dose on the next day (Day 2) after the initial dose will be mandatory, and will be dosed up to 6 days. Maintenance dose on Day 3 and thereafter will follow the transition criteria for maintenance dose.~\<Dose\> A placebo will be injected as needed by intravenous drip infusion once daily. Dilute the study drug 3-to 4-fold using physiological saline for intravenous infusion and then administer the solution over 7 minutes and 30 seconds.
Trial: NCT04417907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy adults will take 2mg placebo PO QD for six weeks
Trial: NCT04175392
Drug: Align Probiotic Supplement Capsule
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Align Probiotic 1 billion units, 1 capsule once daily
Trial: NCT04175392
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebos capsule 1 capsule Once daily
Trial: NCT06380764
Drug: Normal Saline 10 mL Injection
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug
Trial: NCT05297110
Drug: atherolive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In each study population, the patient will be assigned to one of two treatments (atherolive or placebo) using a computer-generated randomization list (1: 1 allocation). The investigator who has the randomization code is not involved in other study procedures and does not interact with participants. The study drug (atherol) will be prescribed at a dose of 400 mg, once a day for 3 months. The placebo will be prescribed identically.
Trial: NCT06211751
Drug: TQB3702 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3702 is a kinase inhibitor.
Trial: NCT06475326
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil: 2400mg/m2, Q2W
Trial: NCT03834909
Drug: Standard dose Truvada®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, one tablet each day
Trial: NCT03834909
Drug: Pregnancy-adjusted dose Truvada®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF/FTC fixed dose combination, 300 mg TDF/200 mg FTC, two tablets each day
Trial: NCT04843046
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be filled with corn starch and riboflavin.
Trial: NCT04848259
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline will be applied after surgery
Trial: NCT06577376
Drug: Simmitinib tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A novel small molecule inhibitor targeting fibroblast growth factor receptor (FGFR), vascular endothelial growth factor receptor (VEGFR2, KDR), and colony-stimulating factor 1 receptor (CSF-1R)
Trial: NCT05700656
Drug: Galunisertib plus capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Combination therapy with galunisertib plus capecitabine
Trial: NCT04889820
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After the surgery, adjuvant chemotherapy will be administered, and total perioperative chemotherapy will be administered with 12 cycles.
Trial: NCT04951713
Drug: XZP-3287 combined with clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: XZP-3287, oral, 120 mg once daily for day 1 and day 12 Drug: clarithromycin, oral, 500 mg twice daily for day 8 to day 21
Trial: NCT06170983
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg once daily for 3 days
Trial: NCT06155487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of Placebo 100 mg
Trial: NCT06155487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of Placebo 200 mg
Trial: NCT06155487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of Placebo 300 mg
Trial: NCT06155487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Single dose of Placebo 400 mg
Trial: NCT06155487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet,Single dose of Placebo 600 mg
Trial: NCT06155487
Drug: AJH-2947 200 mg (MAD)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Tablet, Multiple (once daily for 7days) oral dose of AJH-2947 200 mg
Trial: NCT05681845
Drug: NNC0365-3769 (Mim8)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single dose of Mim8 subcutaneously in the abdomen.
Trial: NCT05742841
Drug: moderate- or high-intensity statin/ rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)
Trial: NCT04836507
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to package insert
Trial: NCT05227768
Drug: VV116 25mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 subjects will receive VV116 25mg,orally; 2 subjects will receive placebo,orally.
Trial: NCT05227768
Drug: VV116 200mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive VV116 200mg,orally; 2 subjects will receive placebo,orally.
Trial: NCT05227768
Drug: VV116 400mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive VV116 400mg,orally; 2 subjects will receive placebo,orally.
Trial: NCT05227768
Drug: VV116 800mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive VV116 800mg,orally; 2 subjects will receive placebo,orally.
Trial: NCT05227768
Drug: VV116 1200mg Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 subjects will receive VV116 1200mg,orally; 2 subjects will receive placebo,orally.
Trial: NCT04958434
Drug: TST005
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TST005 is a bifunctional human immunoglobulin G1 (IgG1) monoclonal
Trial: NCT06548490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be a dry needle stick; no substances will be injected
Trial: NCT05906056
Drug: Zoledronic Acid Injection
RxNorm normalized name: zoledronic acid Injection
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: one dose of intravenous zoledronic acid will be administered
Trial: NCT04118556
Drug: Best available Treatment (BAT)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, vedolizumab, ruxolitinib or infliximab. Dose and frequency will depend on label (where approved) and institutional guidelines for various BAT.